Following their U.S. debut at MDEX in Detroit, the companies are showcasing integrated rugged edge AI concepts at COMPUTEX 2026 and discussing potential future collaboration opportunities in aerial and embedded...

KUNSHAN, China, June 1, 2026 /PRNewswire/ -- The Goodyear Tire & Rubber Company, in collaboration with the China Association of Automobile Manufacturers (CAAM) and the China Road Safety Association (CRSA), conducted...

SHANGHAI, June 1, 2026 /PRNewswire/ -- Bakery China 2026, the 28th edition of the exhibition, concluded successfully on May 23 at the National Exhibition and Convention Center (NECC) in Shanghai, reinforcing...

Millennium Hotels and Resorts unveil a reimagined boutique experience in the heart of Manhattan, celebrating the reopening with an exclusive MyMillennium member offer. NEW YORK, June 1, 2026 /PRNewswire/ --...

SEOUL, South Korea, June 1, 2026 /PRNewswire/ -- WePlay Korea, the global next-generation social entertainment platform, officially launched its 4th anniversary celebration today. To mark this milestone moment, WePlay has...

HO CHI MINH CITY, Vietnam, June 1, 2026 /PRNewswire/ -- With just over 10 days to go, MMA INNOVATE Vietnam 2026 is set to take place on June 10–11, bringing together...

LIUZHOU, China, June 1, 2026 /PRNewswire/ -- On May 31, the 6th LiuGong (000528.SZ) Global Customer Day was held in Liuzhou, China. Mr. Su Zimeng, President of the China Construction...

12 new systems across Hyper, SuperBlade®, FlexTwin™, and GrandTwin® families offer industry-leading core density with up to 576 efficiency cores per server Breakthrough performance-per-watt and energy efficiency designed to lower...

SINGAPORE, June 1, 2026 /PRNewswire/ -- Digital travel platform Agoda has revealed the top emerging destinations among Vietnamese travelers for the upcoming summer travel season, with accommodation search data showing...

CHICAGO, June 1, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T therapy, achieved a 66.7% objective response...